SLAYBACK

Serial Number 88693706
Registration 6330751
700

Registration Progress

Application Filed
Nov 15, 2019
Under Examination
Approved for Publication
Published for Opposition
Registered
Apr 20, 2021

Trademark Image

SLAYBACK

Basic Information

Serial Number
88693706
Registration Number
6330751
Filing Date
November 15, 2019
Registration Date
April 20, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 20, 2021
Registration
Registered
Classes
005

Rights Holder

AZURITY PHARMACEUTICALS, INC.

03
Address
8 CABOT ROAD
SUITE 2000
WOBURN, MA 01801

Ownership History

Slayback Pharma Limited Liability Company

Original Applicant
16
Princeton, NJ

Slayback Pharma Limited Liability Company

Original Registrant
16
Princeton, NJ

AZURITY PHARMACEUTICALS, INC.

New Owner After Registration #1
03
WOBURN, MA

Legal Representation

Attorney
Douglas R. Wolf

USPTO Deadlines

Next Deadline
485 days remaining
Section 8 Declaration Due (Supplemental Register) (Based on registration date 20210420)
Due Date
April 20, 2027
Grace Period Ends
October 20, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

27 events
Date Code Type Description Documents
Mar 19, 2025 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Mar 5, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Jul 16, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 16, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 16, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 16, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jul 16, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Apr 20, 2021 R.SR A REGISTERED-SUPPLEMENTAL REGISTER Loading...
Mar 17, 2021 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Mar 17, 2021 ALIE A ASSIGNED TO LIE Loading...
Mar 17, 2021 CNTA O APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Loading...
Mar 16, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 15, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 15, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 24, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 24, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 24, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 24, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 21, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 20, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 20, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 21, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 21, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 21, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 20, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 21, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 19, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical drugs, preparations and medications for use in the prevention, reduction and treatment of cardiovascular disorders, allergies, anaphylaxis, central nervous system disorders, peripheral nervous system disorders, reproductive health disorders, electrolytic imbalance, caloric imbalance, obesity, nutritional disorders, autoimmune disorders, endocrine disorders, gastrointestinal disorders, inflammatory disorders, dermatological disorders, infectious diseases, hormonal imbalance, pain, complications arising from organ transplantation, cancer, pulmonary disorders, renal disorders, urinary system disorders, ophthalmic disorders, otic disorders, sense organ disorders, dental disorders, musculoskeletal disorders, diabetic disorders, neuromuscular disorders, bone disorders, blood disorders, metabolic disorders, psychosis; pharmaceutical drugs, preparations and medications for use in sedation, analgesia, anaesthesia; pharmaceutical drugs, preparations and medications for use in the prevention, reduction and treatment of senile disorders, sleep disorders, dementia, congenital disease disorders, abnormal gene disorders, hair growth disorders, gynaecological diseases, obstetric disorders, withdrawal syndromes, hormonal disorders, urogenital organ disorders, sexual dysfunction, nausea and vomiting, emesis, migraine, edema, multiple sclerosis, chronic obstructive pulmonary disorder, depression, pregnancy, spasms, hypertension, hypotension, angioedema, fungal diseases, fertility disorders, hyperglycemia, hypoglycemia, post-operative disorders, arthritis, psoriasis and localized fat deposits; pharmaceutical and biological preparations for use in diagnosis, namely, for use as X-ray contrast reagents
First Use Anywhere: 20170000
First Use in Commerce: 20181200

Classification

International Classes
005